Last reviewed · How we verify
Proton Pump Inhibitors (PPI)
Proton pump inhibitors block the hydrogen/potassium ATPase pump in gastric parietal cells, reducing gastric acid secretion.
Proton pump inhibitors block the hydrogen/potassium ATPase pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Proton Pump Inhibitors (PPI) |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | Proton pump inhibitor |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
PPIs irreversibly inhibit the final step of gastric acid production by targeting the proton pump on the secretory surface of parietal cells. This leads to sustained suppression of both basal and stimulated acid secretion, creating an environment conducive to healing of acid-related lesions and symptom relief. The effect is dose-dependent and can reduce acid output by up to 90%.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
- Helicobacter pylori eradication (as part of combination therapy)
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Constipation
- Hypomagnesemia (chronic use)
- Vitamin B12 deficiency (chronic use)
- Clostridium difficile infection (increased risk)
Key clinical trials
- Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD (PHASE2)
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial. (NA)
- OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers (PHASE4)
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction (PHASE4)
- Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor (PHASE2)
- A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Proton Pump Inhibitors (PPI) CI brief — competitive landscape report
- Proton Pump Inhibitors (PPI) updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI